MaxCyte announces strategic platform licensing agreement with Anocca AB

MaxCyte (MXCT) announced the signing of a Strategic Platform License Agreement, SPL, with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte’s Flow Electroporation technology and ExPERT platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell cell therapies. Under the SPL, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue. “We’re proud to partner with Anocca as they advance the development of TCR-T therapeutics through the clinic,” said Maher Masoud, President and CEO of MaxCyte. “We look forward to supporting Anocca with our globally supported, regulatory-proven platform and technical expertise to accelerate clinical manufacturing and cell engineering processes. Our ExPERT platform delivers the robust scalability and flexibility needed to power high-performance, non-viral gene editing workflows across Anocca’s diverse therapeutic pipeline.”